Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase EARLY_PHASE1 1

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Gastrointestinal 1

Conditions

Neoplasms 3Solid Tumor 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Melanoma 1Adenocarcinoma 1

Interventions

Gemcitabine 57Paclitaxel 50Cyclophosphamide 45pembrolizumab 44Carboplatin 41Bevacizumab 38Cisplatin 33Docetaxel 31Fluorouracil 30Nivolumab 29Capecitabine 29Pemetrexed 24Irinotecan 24Oxaliplatin 23Dexamethasone 23Ipilimumab 22Leucovorin 21Radiotherapy 20Sorafenib 19Doxorubicin 19Everolimus 18Cetuximab 18fludarabine 17Albumin-Bound Paclitaxel 17trametinib 15Sunitinib 15Rituximab 15Erlotinib Hydrochloride 15130-nm albumin-bound paclitaxel 15Prednisone 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Neoplasms × LY3022855 × Clear all
NCT03153410 2025-01-09

Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase EARLY_PHASE1 Completed
11 enrolled 14 charts
Gastrointestinal

Adenocarcinoma, Neoplasms, Pancreatic Neoplasms

NCT02265536 2024-10-28

A Study of LY3022855 In Participants With Breast or Prostate Cancer

Eli Lilly and Company

Phase 1 Completed
34 enrolled 17 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT01346358 2024-09-19

A Study of IMC-CS4 in Subjects With Advanced Solid Tumors

Eli Lilly and Company

Phase 1 Completed
52 enrolled 23 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡